South America Melanoma Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Melanoma Diagnostics and Therapeutics Market Trends and Insights

Expanding Immunotherapy and Targeted Therapy Adoption Transforms Therapeutic Mix

The shift from dacarbazine-based chemotherapy to immune checkpoint therapies is reshaping treatment demand across the South America melanoma diagnostics and therapeutics market. A Brazilian private oncology network reported a median overall survival of 34 months among 723 patients with metastatic melanoma who received first-line immune checkpoint inhibitor therapy.^{[1]International Agency for Research on Cancer, “South America Fact Sheet,” Global Cancer Observatory, gco.iarc.who.int}Combination therapies have increased demand for biomarker-guided treatment selection, including BRAF, NRAS, PD-L1, and tumor mutational burden testing. Targeted BRAF and MEK inhibitor combinations remain important for BRAF-mutated disease, supporting demand for oral treatment options. Integrated pathology, molecular testing, and medicine access strengthen care delivery and market access.

Public Sector Anti-PD-1 Incorporation Widens Access, with Structural Constraints

Brazil incorporated nivolumab and pembrolizumab for advanced melanoma into the Unified Health System (SUS) in August 2024, establishing a formal public access pathway. However, only 15.8% of melanoma treatment authorizations included these medicines during the first four years after incorporation. In March 2026, Brazil’s Ministry of Health, MSD, and Instituto Butantan established a Productive Development Partnership for 10 years of domestic pembrolizumab technology transfer. Colombia also covers BRAF PCR testing through its national healthcare system, with each test valued at USD 300. Procurement budgets and pharmacovigilance requirements continue to affect the pace of therapy adoption.

Rising Melanoma Incidence and Referral Capacity Create Uneven Demand

Melanoma incidence varies significantly across South America, resulting in uneven regional demand. Age-standardized incidence ranged from 1.9 per 100,000 in Colombia to 22.4 per 100,000 in Blumenau, Brazil. Brazil and Argentina reported substantial proportions of superficial spreading and nodular melanoma, while acral lentiginous melanoma accounted for 10% to 18% of cases in Colombia. The supplied study attributed 40% of Colombian acral lentiginous melanoma cases to occupational ultraviolet exposure. Brazil’s reported cases increased by 32%, from 1,547 in 2013 to 2,047 in 2023, while stronger referral networks in São Paulo, Rio de Janeiro, and Curitiba support faster diagnosis and treatment initiation.^{[2]Rodrigo Kraft Rovere et al., “Cutaneous Melanoma Incidence in South America A Multi-Country Analysis Covering Brazil, Uruguay, Colombia, Argentina, and Chile,” Brazilian Journal of Oncology, thieme-connect.de}

Advancing Molecular and Digital Pathology Strengthens the Diagnostic Base

Molecular testing and digital pathology are increasingly central to melanoma diagnosis and treatment planning. The Brazilian Society of Pathology’s 2025 guidelines identified excisional biopsy as the preferred approach for suspected melanoma and outlined BRAF testing methods, including RT-PCR, NGS, and VE-1 immunohistochemistry. The guidelines also supported standardized sentinel-node reporting and consistent pathology records. In May 2026, PathAI and A.C.Camargo Cancer Center announced cooperation to expand the AISight platform through public healthcare programs in Brazil. The project uses cloud-based slide sharing and remote specialist review to improve access to pathology expertise.

High Cost and Budget Impact of Advanced Therapies Limits Public Uptake

The high cost of advanced melanoma therapies limits adoption across public healthcare systems. A Brazilian budget impact analysis projected that increasing nivolumab and pembrolizumab penetration to 80% over five years would require additional spending of BRL 564 million (USD 108.98 million). The analysis also identified a 583% increase in per-authorization costs for concurrent nonbiologic medicines. Fiscal constraints in Argentina, Colombia, Peru, and Brazil can delay reimbursement decisions, disrupt procurement continuity, and restrict patient access despite regulatory approval. Consequently, market growth in public settings may remain below the level indicated by disease burden.

Uneven Access to Dermatology, Biopsy, and Oncology Services Limits Realized Potential

Access to screening, biopsy, specialist review, and oncology treatment remains uneven across the region. A 2025 Chilean multicenter cohort found that dermatology screening detected 16.6% of melanoma cases in private care, compared with 3.6% in public care. The cohort also showed that 34.8% of patients with stage IIB to IV disease received systemic therapy, while BRAF and MEK inhibitors remained unavailable in Chile’s public system. Brazil’s national digital pathology survey identified cost, connectivity, and system integration as barriers to broader adoption. Delayed referrals and inconsistent pathology turnaround times can limit timely entry into the diagnostic and treatment pathway.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Diagnostics Gains Share as Biomarker Testing Expands

Therapeutics accounted for 73.21% of the South America melanoma diagnostics and therapeutics market share in 2025, supported by high spending on immune checkpoint inhibitors and longer treatment cycles. Between 28% and 36% of patients in South America presented with stage III or IV disease, driving demand for systemic treatment. Anti-PD-1 regimens and combination protocols replaced chemotherapy as the preferred first-line option for eligible patients. BRAF and MEK inhibitor combinations served patients with BRAF-mutated melanoma, with prevalence ranging from 47% to 53% among advanced cutaneous melanoma patients in Brazil and Chile.

Diagnostics is forecast to grow at a CAGR of 12.67% from 2026 to 2031, making it the faster-growing product category. Biopsy, dermatoscopy, molecular panels, and pathology services support treatment eligibility. The 2025 Brazilian pathology guidelines expanded the role of structured biopsy assessment, BRAF testing, and sentinel-node reporting. Brazil added 1,500 to 2,000 board-certified dermatologists between 2020 and 2025, supporting greater device utilization and earlier biopsy referrals. The Latin American Digital Pathology Association launched in November 2025 to advance whole-slide imaging, AI-assisted diagnostics, and cloud-based collaboration. Argentina and Colombia are beginning to adopt models used in Brazil’s metropolitan oncology centers.

By Route of Administration: Intravenous Route Gains Ground from Combination Therapy

Oral therapies accounted for 46.87% of revenue in 2025 within the therapeutic segment of the South America melanoma diagnostics and therapeutics market. Dabrafenib and trametinib are established oral BRAF and MEK inhibitor options that do not require infusion infrastructure. This format supports treatment through oncology pharmacies and high-complexity medicine programs, particularly in areas with limited infusion capacity. However, utilization remains dependent on mutation testing and public or private reimbursement availability. Local and topical routes represent a smaller share of demand and primarily support intralesional treatment for superficial disease.

Intravenous therapies are forecast to grow at a CAGR of 14.34% from 2026 to 2031, driven by combination immunotherapy with ipilimumab and nivolumab, as well as nivolumab and relatlimab. Bristol Myers Squibb commercially launched OPDUALAG in Brazil in May 2024, following ANVISA registration in November 2023. In June 2026, ANVISA approved KEYTRUDA SC for healthcare-professional administration in one minute in the thigh or abdomen. The subcutaneous formulation supports specialty clinics and day-oncology settings with limited chair capacity. It also improves access to advanced melanoma treatment in secondary cities and private outpatient centers.

By End User: Specialty Clinics Emerge as the Fastest-Growing Delivery Channel

Hospitals and oncology centers accounted for 54.34% of revenue in 2025. Their market position reflects their ability to provide intravenous therapies, surgical biopsies, complex pathology services, and specialist follow-up. Major cancer centers, including A.C.Camargo Cancer Center and Hospital Israelita Albert Einstein in Brazil, anchor high-complexity care. Comparable tertiary centers in Buenos Aires and Santiago play similar roles in their national healthcare systems. The PathAI and A.C.Camargo partnership strengthened the role of major cancer centers in reviewing digital pathology slides across connected networks.

Specialty clinics and dermatology practices are forecast to grow at a CAGR of 11.21% from 2026 to 2031. Subcutaneous pembrolizumab can reduce reliance on conventional infusion centers and shift care to day clinics. Grupo Fleury S.A. and Diagnósticos da América S.A. support BRAF testing, immunohistochemical profiling, and NGS-based companion diagnostics. Their role is expanding as treatment selection increasingly depends on pretreatment mutation profiling. Public oncology hospitals may also play a larger role in administering novel biologics following the November 2025 launch of Vaccimel at Hospital de Oncología María Curie. Academic institutions in Peru and Argentina continue to support clinical research and health technology assessments that can inform future treatment access.

Geography Analysis

Brazil held 47.70% of the South America melanoma diagnostics and therapeutics market share in 2025, supported by its large population and concentrated oncology infrastructure across São Paulo, Rio de Janeiro, and Curitiba. INCA’s 2026 estimates showed the highest melanoma burden in the South and Southeast, where populations of European ancestry represented a larger share of Fitzpatrick skin types I and II. SUS incorporated nivolumab and pembrolizumab for advanced melanoma in August 2020, although adoption remained limited during the first four years after inclusion. The March 2026 pembrolizumab partnership between MSD and Instituto Butantan marked a significant shift in Brazil’s treatment supply structure.

Argentina was the fastest-growing geography in the South America melanoma diagnostics and therapeutics market. Its age-standardized incidence rate stood at 4.1 per 100,000, compared with 5.2 in Uruguay, 3.5 in Chile, and 1.9 in Colombia. Vaccimel was commercially launched in Argentina in November 2025 after more than 30 years of research by scientists affiliated with Fundación Instituto Leloir and CONICET. The allogeneic therapeutic vaccine targeted cutaneous melanoma stages IIB, IIC, and IIIA with intermediate-to-high recurrence risk, with initial administration at Hospital de Oncología María Curie in Buenos Aires. Molecular testing capacity remained uneven outside Buenos Aires and Córdoba, limiting broader adoption of BRAF-guided treatment.

Chile, Colombia, and Peru presented varied access conditions within the South America melanoma diagnostics and therapeutics market. In Chile, a 2025 cohort of 1,037 patients showed stage III to IV incidence of 26.7% in public care, compared with 14.4% in private care. BRAF testing was conducted in 84 of the 1,037 Chilean cases, and 47.6% of tested patients had a BRAF mutation. Colombia’s covered BRAF PCR test provided a structured diagnostic access measure, although treatment procurement remained restricted. Peru’s National Institute of Health issued health technology assessments for encorafenib plus binimetinib in October 2025 and pembrolizumab plus ipilimumab in January 2025.